Fig. 4

Intracranial delivery of exogenous NK cells blocks post-temozolomide recurrence of mesenchymal glioma xenografts. (A) Kaplan-Meier curves indicating responsiveness of subcutaneous GSC1123 xenografts to TMZ treatment (120 mg/kg, i.p) in SCID mice. (B) Kaplan-Meier curves documenting relative refractoriness of intracranial GSC1123 xenografts to TMZ therapy (120 or 200 mg/kg i.p.) in SCID mice. (C) Experimental design of intracranial NK92MI therapy. (D) BLI representative scans of SCID mice in indicated treatment groups: untreated, NK92MI, TMZ + Media or TMZ + NK92MI. (E) Kaplan-Meier curves of GSC1123 tumour bearing mice for corresponding treatment groups show efficacy of TMZ and NK92MI combination. Statistical analysis was conducted by Curve comparison using the Gehan-Breslow-Wilcoxon test. Untreated group (n = 13 mice, 2 repeats), NK92MI treated group (n = 5 mice, 1 repeat), TMZ + media group (n = 15 mice, 4 repeats), TMZ + NK92MI group (n = 6 mice, 2 repeats). (F) Distribution of exogenous NK92MI cells in the brain of mice with GSC1123 xenografts: untreated (left) and TMZ + NK92MI treated mice (right) showing infiltration of NK92MI cells (brown) into the choroid plexus (CP) of lateral ventricle (LV) and meninges (M) 150 days post treatment